Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma

Rituximab is an IgG1, chimeric monoclonal antibody specifically designed to recognize the CD20 antigen expressed on the surface of normal and malignant B-lymphocytes, from the B-cell precursor to the mature B-cells of the germinal center, and by most neoplasms derived from B-cells. After 2 decades o...

Descripción completa

Detalles Bibliográficos
Autores principales: Aguiar-Bujanda, David, Blanco-Sánchez, María Jesús, Hernández-Sosa, María, Galván-Ruíz, Saray, Hernández-Sarmiento, Samuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4629955/
https://www.ncbi.nlm.nih.gov/pubmed/26604821
http://dx.doi.org/10.2147/CMAR.S69145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4629955/
https://www.ncbi.nlm.nih.gov/pubmed/26604821
http://dx.doi.org/10.2147/CMAR.S69145

Ejemplares similares